# Tandem Diabetes Care Inc. (TNDM) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $19.90, market value $1.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Tandem Diabetes Care Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1.3×**. Each dollar of revenue is priced at 1.3×.
- **Price / book: 10.6×**. The shares trade at 10.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -1.9%** (5-yr avg -0.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 56.0%**. Tandem Diabetes Care Inc. keeps 56.0% of revenue after the direct cost of what it sells.
- **Operating margin: -4.4%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -20.2%**. The company reported a net loss over the last twelve months.
- **Return on equity: -131.9%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -9.7%**. Return on all capital, debt included, is -9.7%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -7.2%**. Each dollar of assets produces -7.2% of profit.

## Growth
- **Revenue growth (1 yr): 7.9%** (3-yr 8.2%/yr, 5-yr 15.3%/yr). Revenue grew 7.9% over the last year, against 15.3% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -106.8%**. Earnings per share fell 106.8%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 2.00**. Debt is 2.00 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: net cash**. Tandem Diabetes Care Inc. holds more cash than debt.
- **Altman Z-score: 1.84**. A Z-score of 1.84 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Tandem Diabetes Care Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 60.6%** (YTD -9.5%, 3-mo 2.9%). The shares are up 60.6% over twelve months including dividends.
- **From 52-week high: -32.9%** (73.6% above the low). Trading 33% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): 1.09** (volatility 78%). Beta of 1.09 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TNDM · Page: https://foliofundamentals.com/stocks/tndm

Not investment advice.